ONC PE Ratio & Valuation, Is ONC Overvalued

Historical Valuation

BeOne Medicines AG (ONC) is now in the Fair zone, suggesting that its current forward PE ratio of 68.54 is considered Fairly compared with the five-year average of 79.00. The fair price of BeOne Medicines AG (ONC) is between 40.41 to 564.18 according to relative valuation method.

Relative Value

Fair Zone

40.41-564.18

Current Price：302.29

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is BeOne Medicines AG (ONC) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

BeOne Medicines AG (ONC) has a current Price-to-Book (P/B) ratio of 8.33. Compared to its 3-year average P/B ratio of 6.67, the current P/B ratio is approximately 24.90% higher. Relative to its 5-year average P/B ratio of 6.65, the current P/B ratio is about 25.39% higher. BeOne Medicines AG (ONC) has a Forward Free Cash Flow (FCF) yield of approximately 1.58%. Compared to its 3-year average FCF yield of -0.77%, the current FCF yield is approximately -304.52% lower. Relative to its 5-year average FCF yield of -0.80%, the current FCF yield is about -296.59% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ONC competitors is 4.60, providing a benchmark for relative valuation. BeOne Medicines AG Corp (ONC.O) exhibits a P/S ratio of 5.69, which is 23.75% above the industry average. Given its robust revenue growth of 41.00%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ONC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ONC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ONC currently overvalued or undervalued?

What is BeOne Medicines AG (ONC) fair value?

ONC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BeOne Medicines AG (ONC) is between 40.41 to 564.18 according to relative valuation method.

How does ONC's valuation metrics compare to the industry average?

The average P/S ratio for ONC's competitors is 4.60, providing a benchmark for relative valuation. BeOne Medicines AG Corp (ONC) exhibits a P/S ratio of 5.69, which is 23.75% above the industry average. Given its robust revenue growth of 41.00%, this premium appears sustainable.

What is the current P/B ratio for BeOne Medicines AG (ONC) as of Mar 11 2026?

As of Mar 11 2026, BeOne Medicines AG (ONC) has a P/B ratio of 8.33. This indicates that the market values ONC at 8.33 times its book value.

What is the current FCF Yield for BeOne Medicines AG (ONC) as of Mar 11 2026?

As of Mar 11 2026, BeOne Medicines AG (ONC) has a FCF Yield of 1.58%. This means that for every dollar of BeOne Medicines AG's market capitalization, the company generates 1.58 cents in free cash flow.

What is the current Forward P/E ratio for BeOne Medicines AG (ONC) as of Mar 11 2026?

As of Mar 11 2026, BeOne Medicines AG (ONC) has a Forward P/E ratio of 68.54. This means the market is willing to pay $68.54 for every dollar of BeOne Medicines AG's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BeOne Medicines AG (ONC) as of Mar 11 2026?

As of Mar 11 2026, BeOne Medicines AG (ONC) has a Forward P/S ratio of 5.69. This means the market is valuing ONC at $5.69 for every dollar of expected revenue over the next 12 months.

ONC Valuation